Get started
Aurinia Pharmaceuticals IncAA

Aurinia Pharmaceuticals Inc

7.84USDR
−0.15−1.88%
At close at May 30, 23:30 GMT
USD
No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals Options

AUPH fundamentals

Key facts

Market capitalization‪1.06 B‬USD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)28.93
Basic EPS (TTM)0.28USD
Founded1993
Employees (FY)130
CEOPeter S. Greenleaf
Websiteauriniapharma.com
About

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Ownership
‪‪135.10 M‬‬
Free Float shares
‪‪120.13 M‬‬ (88.92%)
Closely held shares
‪‪14.97 M‬‬ (11.08%)
Free Float shares
‪‪120.13 M‬‬ (88.92%)
Closely held shares
‪‪14.97 M‬‬ (11.08%)
Capital structure
Market cap
‪‪1.06 B‬‬
Debt
‪‪77.91 M‬‬
Cash & equivalents
‪‪312.90 M‬‬
Enterprise value
‪‪824.23 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪1.06 B‬‬
Price to earning ratio (P/E)
28.93x
Price to sales ratio (P/S)
4.63x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
28.93x
Price to sales ratio (P/S)
4.63x
Valuation ratios
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪60.00‬
‪120.00‬
‪180.00‬
‪240.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−40%‬
‪−20%‬
‪0%‬
‪20%‬
‪40%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
‪‪50.00 M‬‬
‪‪75.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪16.00 M‬‬
‪‪32.00 M‬‬
‪‪48.00 M‬‬
‪‪64.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪16.00 M‬‬
‪‪32.00 M‬‬
‪‪48.00 M‬‬
‪‪64.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Therapeutic Drugs
By country
Period: 2024
United States
Japan

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪17.00 M‬‬
‪‪34.00 M‬‬
‪‪51.00 M‬‬
‪‪68.00 M‬‬
Actual
Estimate
Earnings
Next:Jul 31, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪−0.06‬
‪0.00‬
‪0.06‬
‪0.12‬
‪0.18‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
AUPH has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−30.00 M‬‬
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
‪‪90.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪110.00 M‬‬
‪‪220.00 M‬‬
‪‪330.00 M‬‬
‪‪440.00 M‬‬
Assets
Liabilities